For investors only

All about the drug candidate arfolitixorin
and related information

ASCO GI 2025, poster

An abstract with results from a post hoc-analysis of the company’s Phase III-study AGENT will be presented at ASCO GI, which takes place in San Francisco, US, between January 23-25th, 2025.

An external expert group consisting of Göran Carlsson, MD, PhD, Sahlgrenska University Hospital; Åke Hjalmarson, MD, Prof in Cardiology at Sahlgrenska University Hospital, and Aldina Pivodic, PhD, APNC Sweden. It is based on the post-hoc per-protocol analysis of the global phase III-study AGENT conducted earlier this year and is funded by Isofol.

Information about the poster

Title: ”The importance of treatment handling and compliance on overall response rate in a phase III study of metastatic colorectal cancer: Post-hoc per protocol analyses of the AGENT trial”.

Presenter: Aldina Pivodic, PhD, APNC Sweden

Abstract Number: #205

Poster Number: #Bd H17

The abstract was published online on January 21 at 16:00 CET.

Link to the abstract >>

The poster is presented on site on January 25 at 07:00 PST. Link to the poster session schedule.

Link to the poster >>

Last updated 01-27-2025

Scroll to Top